Kansuinine A
Based on 1 Customer Validation
Kansuinine A is a diterpenoid compound. Kansuinine A is isolated from the roots of Euphorbia kansui. Kansuinine A inhibits H2O2-mediated upregulation of phosphorylated IKKβ, NF-κB and IκBα. Kansuinine A inhibits ROS production, reduces the Bax/Bcl-2 ratio and the expression of cleaved Caspase-3. Kansuinine A upregulates the expression of SOCS-3 and blocks IL-6-induced signal transduction. Kansuinine A decreases the expression of LOX-1 and inhibits Apoptosis. Kansuinine A reduces the atherosclerotic lesion area of the aortic arch, improves glucose/insulin tolerance, and enhances antioxidant capacity. Kansuinine A exhibits antiviral and antitumor activities. Kansuinine A can be used in research related to atherosclerosis, liver cancer and type 2 diabetes.
For research use only. We do not sell to patients.
- Purity : 99.81%
- CAS No.: 57701-86-7
- Formula: C37H46O15
- Molecular Weight:730.75
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[2]|
IL-6 |
Caspase 3 |
Bcl-2 |
Bax |
IKKβ |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NIH3T3 | ED50 |
3.28 μg/mL
Compound: 6
|
Survival effect on NGF-dependent mouse NIH/3T3 cells expressing TrkB assessed as cell viability after 2 days by MTT assay
Survival effect on NGF-dependent mouse NIH/3T3 cells expressing TrkB assessed as cell viability after 2 days by MTT assay
|
[PMID: 15387657] |
| NIH3T3 | ED50 |
7.92 μg/mL
Compound: 6
|
Survival effect on NGF-dependent mouse NIH/3T3 cells expressing TrkA assessed as cell viability after 2 days by MTT assay
Survival effect on NGF-dependent mouse NIH/3T3 cells expressing TrkA assessed as cell viability after 2 days by MTT assay
|
[PMID: 15387657] |
In Vitro
Kansuinine A (0.1-3 µM; 60 min-24 h) shows no toxicity to aortic endothelial cells (at concentrations up to 3 µM), and protects these cells against H2O2-induced viability loss at concentrations of 0.1, 0.3 and 1.0 µM[1].
Kansuinine A (0.1-1.0 µM; 1 h) concentration-dependently reduces H2O2-induced intracellular reactive oxygen species production in aortic endothelial cells at concentrations of 0.1, 0.3, and 1.0 µM[1].
Kansuinine A (0.1-1 μM; 1 h) restores the activities of GPx and SOD antioxidant enzymes in AC3RL-treated RIN-m5F rat pancreatic β cells[3].
Kansuinine A (0.1-1.0 µM; 30 min) inhibits H2O2-induced apoptosis in human aortic endothelial cells at concentrations of 0.3 and 1.0 µM, through mechanisms involving the maintenance of cell membrane integrity and the reduction of chromosome damage[1].
Kansuinine A (0.1-1.0 µM; 1 h) attenuates H2O2-induced activation of the pro-apoptotic signaling pathway in human aortic endothelial cells by reducing the Bax/Bcl-2 ratio at concentrations of 0.3 and 1.0 µM, and decreasing the expression of activated caspase-3 at a concentration of 1.0 µM[1].
Kansuinine A (0.1-1 μM) inhibits AC3RL-induced apoptosis of RIN-m5F rat pancreatic β cells[3].
Kansuinine A (0.03-3 μM; 1 h) dose-dependently inhibits IL-6-induced Stat3-dependent luciferase activity in hepatocellular carcinoma HepG2 cells, with significant inhibition observed across the concentration range of 0.03 μM to 3 μM[2].
Kansuinine A (6 μM; 15-120 min) increases the SOCS-3 mRNA expression level by approximately 17-fold in human hepatoma HepG2 cells at 60 min of treatment, and this effect depends on the PKC and MEK/ERK signaling pathways[2].
Kansuinine A (6 μM; 5-60 min) induces sustained ERK1/2 phosphorylation in hepatocellular carcinoma HepG2 cells[2].
Kansuinine A (6 μM; 5-60 min) induces sustained phosphorylation of Stat3 at serine (Ser727) in human hepatoma HepG2 cells over a duration of 5 to 60 minutes, and this effect depends on the PKC and MEK/ERK signaling pathways[2].
Kansuinine A (0.78-12.50 μg/mL; 1 day) significantly promotes the proliferation of peripheral splenic lymphocytes in mice, and its optical density value increases statistically significantly compared with that of the control group[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human aortic endothelial cells (HAECs)
-
Concentration:0.1-3 µM (0.3, 1, 3 µM for toxicity testing; 0.1, 0.3, 1.0 µM for injury protection testing)
-
Incubation Time:24 h (toxicity testing); 60 min pre-incubation followed by 24 h H2O2 challenge (injury protection testing)
-
Result:Showed no significant cytotoxic effect on HAECs at concentrations up to 3 µM (p = 0.62, n = 3).
Protected HAECs from H2O2-induced cell damage, with significant effects observed at 0.1 µM (p < 0.01), 0.3 µM (p < 0.05), and 1.0 µM (p < 0.01, n = 3).
-
Cell Line:human aortic endothelial cells (HAECs)
-
Concentration:0.1-1.0 µM
-
Incubation Time:30 min pre-incubation followed by 24 h H2O2 challenge
-
Result:Reduced chromosomal breakage fragments and maintained cell membrane integrity in H2O2-treated HAECs.
Showed significant reduction in apoptosis rate at 0.3 µM and 1.0 µM (p < 0.001 vs.
H2O2 alone, n = 3).
-
Cell Line:human aortic endothelial cells (HAECs)
-
Concentration:0.1-1.0 µM
-
Incubation Time:1 h pre-incubation followed by 24 h H2O2 challenge
-
Result:Reduced the H2O2-induced Bax/Bcl-2 ratio at 0.3 and 1.0 µM (p < 0.05 vs.
H2O2 alone, n = 3).
Reversed H2O2-induced cleaved caspase-3 expression at 1.0 µM (p < 0.001 vs.
H2O2 alone, n = 3).\nReduced phosphorylated IKKβ levels at 1.0 µM (p < 0.01 vs.
H2O2 alone).
Reduced phosphorylated IκBα levels at 0.3 µM (p < 0.05) and 1.0 µM (p < 0.01 vs.
H2O2 alone).
Reduced phosphorylated NF-κB p65 levels at 0.3 and 1.0 µM (p < 0.05 vs.
H2O2 alone, n = 3).
In Vivo
Kansuinine A (20-60 μg/kg; i.p.; three times weekly; 15 weeks) improves glucose and insulin tolerance, enhances systemic antioxidant capacity, reduces pancreatic β-cell apoptosis, and inhibits NF-κB pathway activation in dyslipidemic, hyperglycemic ApoE−/− mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Apolipoprotein E-deficient (ApoE-/-) mice (C57BL/6 background, n=5 per group, high-fat diet fed for 15 weeks)[1]
-
Dosage:20 µg/kg; 60 µg/kg
-
Administration:i.p.; three times a week; 15 weeks
-
Result:Significantly reduced body weight AUC values compared to HFD-only mice (p < 0.001).
Significantly lowered total cholesterol, LDL-cholesterol, and triglyceride levels compared to HFD-only mice (p < 0.05); the 60 µg/kg group significantly increased HDL-cholesterol levels (p < 0.05).
Reduced aortic arch lesion area by 23% in the 20 µg/kg group (p < 0.05) and by 61% in the 60 µg/kg group (p < 0.001) compared to HFD-only mice.
Significantly reduced mRNA expression of Bax (p < 0.05) and caspase-3 (p < 0.001), and protein expression of Bax and cleaved caspase-3 (p < 0.001) in aortic tissues compared to HFD-only mice.
Significantly increased aortic glutathione peroxidase (GPx) levels (p < 0.001) and significantly reduced aortic malondialdehyde (MDA) levels (p < 0.001) compared to HFD-only mice.
-
Animal Model:ApoE−/− C57BL/6 (10 weeks old, 20-25 g, mixed gender, fed high-fat diet for 15 weeks)[3]
-
Dosage:20 μg/kg; 60 μg/kg
-
Administration:i.p.; three times weekly; 15 weeks
-
Result:Significantly reduced body weight compared to untreated controls.
Significantly reduced serum triglycerides, total cholesterol, and LDL-C levels, and upregulated HDL-C levels at 60 μg/kg dose; reduced the ApoC3/ApoB-100 ratio in plasma at both doses.
Significantly reduced fasting blood glucose levels, decreased the area under the curve for intraperitoneal glucose tolerance tests and insulin tolerance tests, and lowered elevated plasma insulin levels compared to untreated controls at both doses.
Significantly increased pancreatic islet area, reduced TUNEL-positive apoptotic cell percentage in islets, and increased plasma glutathione peroxidase, superoxide dismutase, and catalase activity compared to untreated controls at both doses.
Significantly reduced plasma malondialdehyde levels and dose-dependently decreased pancreatic islet expression of phosphorylated NF-κB, total NF-κB, and cleaved caspase-3 compared to untreated controls at both doses.
Chemical Information
-
CAS No. 57701-86-7
-
Appearance Solid
-
Molecular Weight 730.75
-
Formula C37H46O15
-
Color White to off-white
-
SMILES
O=C1[C@@]2([H])C(C)(C)[C@H](OC(C)=O)[C@H](OC(C3=CC=CC=C3)=O)[C@@H](OC(C)=O)C([C@H](OC(C)=O)[C@]([C@@H](OC(C)=O)[C@@H](C)C4)([H])[C@@]4(OC(C)=O)[C@@](O2)(O)[C@@H]1C)=C
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (136.85 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.42 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (300 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chen CS, et al. Kansuinine A Ameliorates Atherosclerosis and Human Aortic Endothelial Cell Apoptosis by Inhibiting Reactive Oxygen Species Production and Suppressing IKKβ/IκBα/NF-κB Signaling. International journal of molecular sciences. 2021 Sep 24;22(19):10309. [Content Brief]
[2]. Chang JS, et al. Kansuinine A and Kansuinine B from Euphorbia kansui L. inhibit IL-6-induced Stat3 activation. Planta medica. 2010 Oct;76(14):1544-9. [Content Brief]
[3]. Lulji Taraqaz BP, et al. Pancreatic β-cell apoptosis caused by apolipoprotein C3-rich low-density lipoprotein is attenuated by kansuinine A through oxidative stress inhibition. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Jun;187:118066. [Content Brief]
[4]. Shu X, et al. Bioassay-guided separation of the proinflammatory constituents from the roots of Euphorbia kansui. Journal of natural medicines. 2010 Jan;64(1):98-103. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.3685 mL | 6.8423 mL | 13.6846 mL | 34.2114 mL |
| 5 mM | 0.2737 mL | 1.3685 mL | 2.7369 mL | 6.8423 mL | |
| 10 mM | 0.1368 mL | 0.6842 mL | 1.3685 mL | 3.4211 mL | |
| 15 mM | 0.0912 mL | 0.4562 mL | 0.9123 mL | 2.2808 mL | |
| 20 mM | 0.0684 mL | 0.3421 mL | 0.6842 mL | 1.7106 mL | |
| 25 mM | 0.0547 mL | 0.2737 mL | 0.5474 mL | 1.3685 mL | |
| 30 mM | 0.0456 mL | 0.2281 mL | 0.4562 mL | 1.1404 mL | |
| 40 mM | 0.0342 mL | 0.1711 mL | 0.3421 mL | 0.8553 mL | |
| 50 mM | 0.0274 mL | 0.1368 mL | 0.2737 mL | 0.6842 mL | |
| 60 mM | 0.0228 mL | 0.1140 mL | 0.2281 mL | 0.5702 mL | |
| 80 mM | 0.0171 mL | 0.0855 mL | 0.1711 mL | 0.4276 mL | |
| 100 mM | 0.0137 mL | 0.0684 mL | 0.1368 mL | 0.3421 mL |
Keywords
- Kansuinine A
- 57701-86-7
- Interleukin Related
- IKK
- NF-κB
- Reactive Oxygen Species (ROS)
- Bcl-2 Family
- Caspase
- LOX-1
- Apoptosis
- SOCS-3
- Euphorbia kansui roots
- IKKβ/NF-κB signaling pathway
- atherosclerosis
- ApoE-/- mice
- ERK1/2
- RIN-m5F rat pancreatic β-cells
- human aortic endothelial cells
- Stat3
- human hepatoma HepG2 cells
- Inhibitor
- inhibitor
- inhibit